Disease-modifying drugs and Parkinson's disease.
Identifieur interne : 002320 ( Main/Exploration ); précédent : 002319; suivant : 002321Disease-modifying drugs and Parkinson's disease.
Auteurs : Hervé Allain [France] ; Danièle Bentué-Ferrer ; Yvette AkwaSource :
- Progress in neurobiology [ 0301-0082 ] ; 2008.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (pharmacology), Apoptosis (drug effects), Apoptosis (genetics), Brain (drug effects), Brain (metabolism), Brain (physiopathology), Cytoprotection (drug effects), Cytoprotection (physiology), Disease Models, Animal, Humans, Nerve Degeneration (drug therapy), Nerve Degeneration (genetics), Nerve Degeneration (physiopathology), Neuroprotective Agents (pharmacology), Parkinson Disease (drug therapy), Parkinson Disease (genetics), Parkinson Disease (physiopathology).
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Neuroprotective Agents.
- drug effects : Apoptosis, Brain, Cytoprotection.
- drug therapy : Nerve Degeneration, Parkinson Disease.
- genetics : Apoptosis, Nerve Degeneration, Parkinson Disease.
- metabolism : Brain.
- physiology : Cytoprotection.
- physiopathology : Brain, Nerve Degeneration, Parkinson Disease.
- Animals, Disease Models, Animal, Humans.
Abstract
Symptomatic medications, l-Dopa and dopaminergic agents, remain the only clinically pertinent pharmacological treatment proven effective and available for the large population of patients with Parkinson's disease. The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease. The purpose of this review, based on recent biological and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease. Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clinical trials. It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases.
DOI: 10.1016/j.pneurobio.2007.10.003
PubMed: 18037225
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D32
- to stream PubMed, to step Curation: 000C92
- to stream PubMed, to step Checkpoint: 000C92
- to stream Ncbi, to step Merge: 000788
- to stream Ncbi, to step Curation: 000788
- to stream Ncbi, to step Checkpoint: 000788
- to stream Main, to step Merge: 002521
- to stream Main, to step Curation: 002320
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Disease-modifying drugs and Parkinson's disease.</title>
<author><name sortKey="Allain, Herve" sort="Allain, Herve" uniqKey="Allain H" first="Hervé" last="Allain">Hervé Allain</name>
<affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bentue Ferrer, Daniele" sort="Bentue Ferrer, Daniele" uniqKey="Bentue Ferrer D" first="Danièle" last="Bentué-Ferrer">Danièle Bentué-Ferrer</name>
</author>
<author><name sortKey="Akwa, Yvette" sort="Akwa, Yvette" uniqKey="Akwa Y" first="Yvette" last="Akwa">Yvette Akwa</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18037225</idno>
<idno type="pmid">18037225</idno>
<idno type="doi">10.1016/j.pneurobio.2007.10.003</idno>
<idno type="wicri:Area/PubMed/Corpus">000D32</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D32</idno>
<idno type="wicri:Area/PubMed/Curation">000C92</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C92</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000C92</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C92</idno>
<idno type="wicri:Area/Ncbi/Merge">000788</idno>
<idno type="wicri:Area/Ncbi/Curation">000788</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000788</idno>
<idno type="wicri:doubleKey">0301-0082:2008:Allain H:disease:modifying:drugs</idno>
<idno type="wicri:Area/Main/Merge">002521</idno>
<idno type="wicri:Area/Main/Curation">002320</idno>
<idno type="wicri:Area/Main/Exploration">002320</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Disease-modifying drugs and Parkinson's disease.</title>
<author><name sortKey="Allain, Herve" sort="Allain, Herve" uniqKey="Allain H" first="Hervé" last="Allain">Hervé Allain</name>
<affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bentue Ferrer, Daniele" sort="Bentue Ferrer, Daniele" uniqKey="Bentue Ferrer D" first="Danièle" last="Bentué-Ferrer">Danièle Bentué-Ferrer</name>
</author>
<author><name sortKey="Akwa, Yvette" sort="Akwa, Yvette" uniqKey="Akwa Y" first="Yvette" last="Akwa">Yvette Akwa</name>
</author>
</analytic>
<series><title level="j">Progress in neurobiology</title>
<idno type="ISSN">0301-0082</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Apoptosis (drug effects)</term>
<term>Apoptosis (genetics)</term>
<term>Brain (drug effects)</term>
<term>Brain (metabolism)</term>
<term>Brain (physiopathology)</term>
<term>Cytoprotection (drug effects)</term>
<term>Cytoprotection (physiology)</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Nerve Degeneration (drug therapy)</term>
<term>Nerve Degeneration (genetics)</term>
<term>Nerve Degeneration (physiopathology)</term>
<term>Neuroprotective Agents (pharmacology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (genetics)</term>
<term>Parkinson Disease (physiopathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term>
<term>Brain</term>
<term>Cytoprotection</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Apoptosis</term>
<term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cytoprotection</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term>
<term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Symptomatic medications, l-Dopa and dopaminergic agents, remain the only clinically pertinent pharmacological treatment proven effective and available for the large population of patients with Parkinson's disease. The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease. The purpose of this review, based on recent biological and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease. Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clinical trials. It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Région Bretagne</li>
</region>
<settlement><li>Rennes</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Akwa, Yvette" sort="Akwa, Yvette" uniqKey="Akwa Y" first="Yvette" last="Akwa">Yvette Akwa</name>
<name sortKey="Bentue Ferrer, Daniele" sort="Bentue Ferrer, Daniele" uniqKey="Bentue Ferrer D" first="Danièle" last="Bentué-Ferrer">Danièle Bentué-Ferrer</name>
</noCountry>
<country name="France"><region name="Région Bretagne"><name sortKey="Allain, Herve" sort="Allain, Herve" uniqKey="Allain H" first="Hervé" last="Allain">Hervé Allain</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002320 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002320 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:18037225 |texte= Disease-modifying drugs and Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18037225" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |